Dehydroepiandrosterone indirectly inhibits human osteoclastic resorption via activating osteoblastic viability by the MAPK pathway

Chinese Medical Journal

Volumn 125, Issue 7, 2012, Pages 1230-1235

  Wang, Yu Dong ^a   Tao, Min Fang ^a   Cheng, Wei Wei ^a   Liu, Xiao Hua ^a   Wan, Xiao Ping ^a   Cui, Ke Mi ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Dehydroepiandrosterone; MAP kinase signaling pathways; Osteoblasts; Osteoclast

Indexed keywords

1, 4 DIAMINO 1, 4 BIS (2 AMINOPHENYLTHIO) 2, 3 DICYANOBUTADIENE; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PRASTERONE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CATTLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; BUTADIENES; CELL PROLIFERATION; CELLS, CULTURED; DEHYDROEPIANDROSTERONE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMMUNOBLOTTING; MITOGEN-ACTIVATED PROTEIN KINASES; NITRILES; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84859966513     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.07.008     Document Type: Article

References (33)

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
2. Enserink M. Women's health. The vanishing promises of hormone replacement. Science 2002; 297: 325-326.
3. Balasch J. Sex steroids and bone: current perspectives. Hum Reprod Update 2003; 9: 207-22.
4. Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M, et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 2010; 123: 1060-1064.
5. Manolagas SC, Kousteni S. Perspective: nonreproductive sites of action of reproductive hormones. Endocrinology 2001; 142: 2200-2204.
6. Grumbach MM. Estrogen, bone, growth and sex: a sea change in conventional wisdom. J Pediatr Endocrinol Metab 2000; 13 Suppl 6: 1439-1455.
7. Chen JR, Kousteni S, Bellido T, Han L, DiGregorio GB, Jilka RL, et al. Gender-independent induction of murine osteoclast apoptosis in vitro by either estrogens or non-aromatizable androgens. J Bone Miner Res 2001; 16 (Suppl 1): S159.
8. Yoshida S, Honda A, Matsuzaki Y, Fukushima S, Tanaka N, Takagiwa A, et al. Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. Steroids 2003; 68: 73-83.
9. Araghi-Niknam M, Ardestani SK, Molitor M, Inserra P, Eskelson CD, Watson RR. Dehydroepiandrosterone (DHEA) sulfate prevents reduction in tissue vitamin E and increased lipid peroxidation due to murine retrovirus infection of aged mice. Proc Soc Exp Biol Med 1998; 218: 210-217.
10. Cormier C, Souberbielle JC, Kahan A. DHEA in bone and joint diseases. Joint Bone Spine 2001; 68: 588-594.
11. Wang L, Wang YD, Wang WJ, Li DJ. Differential regulation of dehydroepiandrosterone and estrogen on bone and uterus in ovariectomized mice. Osteoporos Int 2009; 20: 79-92.
12. Wang L, Wang YD, Wang WJ, Zhu Y, Li DJ. Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. J Mol Endocrinol 2007; 38: 467-479.
13. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 1998; 250: 229-234.
14. Kim YH, Kim GS, Jeong-Hwa B. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 2002; 34: 145-151.
15. Ogata N, Chikazu D, Kubota N, Terauchi Y, Tobe K, Azuma Y, et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 2000; 105: 935-943.
16. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001; 104:719-730.
17. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003; 423: 349.
18. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289: 1504-1508.
19. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002; 416: 744-749.
20. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14367.
21. Alliston T, Derynck R. Medicine: interfering with bone remodelling. Nature 2002; 416: 686-687.
22. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-3602.
23. Yang L, Hai Y, Zhou JL. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation. Chin Med J 2011; 124: 2033-2037
24. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247: 610-615.
25. Wang YD, Luo LM, Tong JQ, Li DJ. Experimental study of Dehydroepiandrosterone for inhibiting osteoblastic apoptosis. Chin J Obst Gyn (Chin) 2005; 40: 844-845.
26. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010; 468: 103-107.
27. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010; 468: 98-102.
28. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW. ERbeta has nongenomic action in caveolae. Mol Endocrinol 2002; 16: 938-946.
29. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002; 57: 385-409.
30. Yuan Y, Wu ZJ, Yao HY, Yu XD, Guo ZK, Chen XS, et al. Activation of p38 mitogen-activated protein kinase contribute to BMP4-induced alkaline phosphatase expression in MC3T3-E1 preosteoblast. Chin Med J 2006; 119: 324-327.
31. Kawamura N, Kugimiya F, Oshima Y, Ohba S, Ikeda T, Saito T, et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS One 2007; 2: e1058.
32. Nawata H, Yanase T, Goto K, Okabe T, Ashida K. Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S. Mech Ageing Dev 2002; 123: 1101-1106.
33. Yang L, Tao T, Wang X, Du N, Chen W, Tao S, et al. Effects of dexamethasone on proliferation, differentiation and apoptosis of adult human osteoblasts in vitro. Chin Med J 2003; 116: 1357-1360.